Plasma cell myeloma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:13:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Plasma cell myeloma recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Continuous and Fixed Duration Therapy with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Relapsed Multiple Myeloma https://clinicaltrials.eu/trial/study-comparing-continuous-and-fixed-duration-therapy-with-daratumumab-lenalidomide-and-dexamethasone-for-patients-with-relapsed-multiple-myeloma/ Wed, 29 Apr 2026 15:02:08 +0000 https://clinicaltrials.eu/trial/study-comparing-continuous-and-fixed-duration-therapy-with-daratumumab-lenalidomide-and-dexamethasone-for-patients-with-relapsed-multiple-myeloma/ This clinical trial is focused on studying a type of blood cancer called multiple myeloma, which affects the plasma cells in the bone marrow. The study is investigating the effectiveness of a combination of medications: Daratumumab, Lenalidomide, and Dexamethasone. Daratumumab, also known by its code name HuMax-CD38, is a protein-based treatment given through an injection. Lenalidomide is taken orally, and Dexamethasone can be administered both orally and intravenously. The purpose of the study is to compare two different treatment approaches: continuous therapy versus a fixed duration of therapy for patients whose multiple myeloma has returned after initial treatment.

Participants in the study will receive one of the two treatment plans. The continuous therapy group will receive the medications until the disease progresses, while the fixed duration group will receive the medications for a set period of 24 months. The study aims to determine if the fixed duration treatment is as effective as the continuous treatment in terms of overall survival over four years. Throughout the study, participants will be monitored regularly to assess their response to the treatment and any side effects they may experience.

The trial will also evaluate the quality of life of participants using questionnaires and analyze the cost-effectiveness of the treatments. The study is designed to provide valuable information on the best treatment approach for relapsed multiple myeloma, helping to improve patient care and outcomes in the future.

]]> Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma https://clinicaltrials.eu/trial/study-comparing-subcutaneous-and-intravenous-isatuximab-with-pomalidomide-and-dexamethasone-for-adults-with-relapsed-or-refractory-multiple-myeloma/ Wed, 29 Apr 2026 14:29:26 +0000 https://clinicaltrials.eu/trial/study-comparing-subcutaneous-and-intravenous-isatuximab-with-pomalidomide-and-dexamethasone-for-adults-with-relapsed-or-refractory-multiple-myeloma/ This clinical trial is focused on studying a type of cancer called multiple myeloma, which affects plasma cells in the bone marrow. The study is testing a combination of medications to see how well they work together. The medications being tested include isatuximab, pomalidomide, and dexamethasone. Isatuximab is given in two different ways: as a subcutaneous injection (under the skin) and as an intravenous infusion (into a vein). Pomalidomide and dexamethasone are taken orally in capsule and tablet forms, respectively.

The purpose of the study is to compare the effectiveness of the subcutaneous and intravenous methods of administering isatuximab when used with pomalidomide and dexamethasone. Participants in the study will receive one of these combinations and may also receive a placebo. The study will last for a period of up to 80 weeks, during which participants will be monitored regularly to assess their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on how well the treatment works, how the body processes the medications, and the overall health and satisfaction of the participants. This information will help determine if the subcutaneous method of administering isatuximab is as effective as the intravenous method, potentially offering a more convenient option for patients with multiple myeloma in the future.

]]>